Aetion, HealthVerity collaborate on real-world data for COVID-19 treatments, Aptar Pharma, Sonmol co-developing digital respiratory offerings and more digital health deals

Also: HomeStay to distribute, integrate G Medical's remote monitoring tech; Imprivata and Microsoft announce new health IT security offerings.
By Dave Muoio
02:54 pm
Share

Real-world evidence platforms Aetion and HealthVerity are playing to their strengths with the joint launch of new tools to support biopharmas and regulators gauging new COVID-19 treatments. The first, called the Real-Time Evidence Platform, is built on an instance of Aetion's platform and focuses on up-to-date usage, safety and effectiveness data. The Real-Time Trend Reporting and Interactive Data Visualizer, meanwhile, looks to demonstrate COVID-19's overall impact and how patients are currently accessing health care.

“As the industry moves to accelerate interventions for the treatment and prevention of COVID-19, the stakes are incredibly high,” Carolyn Magill, CEO of Aetion, said in a statement. “Our offerings use HealthVerity’s comprehensive, real-time data to obtain decision-ready insights that can help meet the need for accelerated approvals and access, while maintaining our high bar for evidence to support critical safety and effectiveness determinations.” 


Chinese digital respiratory therapeutics firm Sonmol will be collaborating with AptarGroup's Aptar Pharma on a new therapy and services platform that will incorporate remote patient-monitoring for respiratory and other diseases, the companies announced yesterday. To start, the partners will focus on connected drug-delivery devices for asthma and COPD.

“Aptar Pharma has a well-established position worldwide in drug delivery technologies across the whole value chain," Luffy Lv, CEO of Sonmol, said in a statement. "Collaborating with Aptar will help us expand and speed up clinical application and commercialization of Sonmol’s innovative products. I look forward to more in-depth and innovative exploration and collaboration between Aptar and Sonmol in the field of drug and disease digital management in China and worldwide.”

Alongside the partnership, Aptar Pharma also noted a strategic equity investment into Sonmol. The sum of this investment was not disclosed.


G Medical Innovations has cut a deal with HomeStay Care Limited that will see the latter distribute G Medical's Prizma remote monitoring device in Australia and New Zealand. Further, Prizma will be integrated into HomeStay's internet of things network, providing the company's uVue telehealth platform with remote vital-sign-monitoring capabilities.

“We have reviewed several solutions over the past few months with a focus on seamless integration to the uVue telehealth platform," Graham Russell, managing director at HomeStay, said in a statement. "Usability being forefront in the aged care space, we feel that the Prizma platform exceeded our requirements, and we are looking forward to working with the G Medical team on the offering.”


Healthcare IT security company Imprivata deepened its partnership with Microsoft with yesterday's announcement of new digital identify products, which it will be working with the tech giant to sell jointly.

As the name suggests, Imprivata Identity Governance for Microsoft Azure makes the security company's identity governance and compliance management tech available within the Azure environment. Meanwhile, Imprivata OneSign for single sign-on across any device or application has now been integrated with Azure Active Directory.

"As shared mobile devices become a mainstay at many points of patient care, we’re pleased to work with Imprivata to continue to improve the security of Surface devices and mobile and web applications like Microsoft Teams, without disrupting clinical workflows,” Andrea McGonigle, U.S. national managing director for Microsoft Health & Life Sciences, said in a statement. “We look forward to working with Imprivata as we continue to innovate to provide joint digital identity solutions that are purpose-built for hybrid healthcare.”


Causaly, a tech company using artificial intelligence to interpret large datasets and literature, will be helping London's Global University (UCL) with its COVID-19 research. These efforts include the development and delivery of low-cost breathing aids, antiviral candidate trials and rapid sequencing of the disease.

“As a medical researcher working at the interface between care and research, Causaly allows me to rapidly ingest, analyze and derive insights from huge amounts of biomedical literature," Spiros Denaxas, a professor at the UCL Institute of Health Informatics, said in a statement. Importantly, it allows us to focus on the translation of our research by enabling us to triangulate evidence derived from research and clinical guidelines.”